Qure AI
Qure.ai is a Mumbai-headquartered healthcare AI company that builds FDA-cleared deep-learning algorithms to interpret chest X-rays, head CTs, chest CTs, and ultrasounds, deployed across 5,500+ sites in 105+ countries via direct hospital sales, OEM embedding, and government public-health programs.
- Company typePrivate
- Founded2016
- HeadquartersAndheri, India
- Headcount251–500
- GTM typeB2B
- OfferingSoftware
What Qure AI does
Qure.ai Technologies Private Limited is a Mumbai-headquartered healthcare AI company founded in 2016 by Prashant Warier that develops deep-learning computer-vision models for automated interpretation of radiology exams (chest X-ray, head CT, chest CT, MSK X-ray) and, more recently, ultrasound. Its product portfolio is anchored by qXR (chest X-ray reporting with 26 FDA-cleared indications across 9 products), supported by qER (stroke/TBI head CT), qCT LN Quant (lung nodule management), qMSK, qTrack (care coordination), qScout (population surveillance), and the Aira clinical AI co-pilot for LMICs; algorithms are trained on more than 1 billion medical images and are deployed as cloud or on-premise services integrated with PACS/RIS and OEM imaging platforms.
The company monetizes primarily through enterprise SaaS subscriptions to hospital systems and NHS trusts, per-study/per-deployment licensing to OEM and platform partners (Fujifilm, Siemens Healthineers, Philips, Blackford, Medtronic, Nuance), managed-services contracts with national and state public health programs (Telangana, Goa, Maharashtra, Lesotho, Mozambique, Oman), professional-services arrangements with pharma and life-sciences customers (AstraZeneca, Project Data Sphere, Roche Startup Creasphere), and non-dilutive grant funding (Gates Foundation $8M, SBRI/NHS £3.2M). Its go-to-market combines direct enterprise sales ([email protected]) with OEM embedding, channel resellers (Medica Group, InHealth, USARAD, Strategic Radiology, Unilabs, deepc, Healthcare Imaging Services), NGO/global-health partners (PATH, VillageReach, IHVN, CIDRZ), and event-led demand generation across RSNA, ASCO, ATS, and the India AI Impact Summit.
Qure.ai reports reaching 45M+ lives across 105+ countries via 5,500+ sites, holds 40 patents, and is referenced in a 2026 source as a subsidiary of Fractal Analytics; it has raised approximately $130M cumulatively, including a $65M Series D in September 2024 led by Lightspeed and 360 ONE Asset. The company maintains offices in Mumbai, Bengaluru, New York, and Birmingham, and counts the FDA, EU MDR, Health Canada, and the WHO (for autonomous TB screening) among its regulatory endorsements.
Qure AI firmographics
Firmographics- Name
- Qure AI
- Legal name
- Qure.ai Technologies Private Limited
- Website
- https://qure.ai
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Qure.ai is a Mumbai-headquartered healthcare AI company that builds FDA-cleared deep-learning algorithms to interpret chest X-rays, head CTs, chest CTs, and ultrasounds, deployed across 5,500+ sites in 105+ countries via direct hospital sales, OEM embedding, and government public-health programs.
- Ownership category
- akta.pro rank
Qure AI industry classification
Industry- Product category
- Medical Imaging AI
- NAICS
- Software Publishers (51321), Diagnostic Imaging Centers (621512)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
- akta.pro secondary industries
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)
Keywords
Where Qure AI is headquartered
LocationHeadquarters
- HQ city
- Andheri
- HQ country
- India
- HQ region
- Asia
Offices4 records
Markets served
Qure AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Enterprise SaaS subscriptions: Subscription-based deployment of qXR, qER, qCT, qTrack, and qMSK AI platforms to hospital systems, NHS trusts, teleradiology firms, and government health programs. Recurring contracts tied to deployment scope, volume, and integrations.
- OEM/embedded licensing: Per-study/per-deployment licensing to OEM and platform partners including Fujifilm (REiLI), Siemens Healthineers, Philips, Blackford, Medtronic, and Nuance, who embed Qure.ai algorithms into their own products and services.
- Government and public health program contracts: Direct contracts with state health ministries and national TB/lung cancer programs (Telangana, Goa, Maharashtra, Bihar, Lesotho, South Africa, Mozambique, Philippines) for population-scale AI screening deployments.
- Pharma & life sciences clinical trial services: AI-derived biomarker and care coordination services for pharmaceutical R&D and clinical trials, including partnership with Project Data Sphere on autoRECIST for tumor burden measurement and AstraZeneca A.Catalyst Network collaborations.
- Grants and non-dilutive funding: Multi-million-dollar grants from foundations such as the Gates Foundation ($8M for AI-powered point-of-care ultrasound and open-source multi-modal lung health database) and SBRI Healthcare / NHS Cancer Programme (£3.2M).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based enterprise contracts via [email protected] |
Go-to-market motion5 records
Distribution channels5 records
Marketing channels8 records
Qure AI product offering
Product offeringCore offering
Qure AI develops deep-learning medical imaging software that interprets chest X-rays, head CTs, chest CTs, and musculoskeletal X-rays for clinical decision support. Its portfolio (qXR, qER, qCT LN Quant, qTrack, qMSK, Aira, qXR-CTR) is sold to hospitals, NHS trusts, teleradiology firms, government public-health programs, OEM imaging vendors, and pharmaceutical/life-sciences organizations.
Product overview
Qure.ai offers a single unified AI healthcare platform combining a portfolio of deep-learning medical imaging products deployed across 5,500+ sites in 105+ countries. The portfolio is anchored by qXR (chest X-ray reporting) as the core imaging product, supported by qER (stroke and TBI head CT analysis), qMSK (musculoskeletal X-ray), and Heart Failure (qXR-CTR) modules, with qTrack providing care coordination and TB cascade management. The Lung Nodule Management module (including qCT LN Quant) extends the platform to end-to-end lung cancer care, while Aira acts as a multi-disease clinical AI co-pilot for resource-constrained settings. Together these products cover the full clinical workflow from screening and triage to diagnosis, quantification, and longitudinal case management.
Differentiator
Problem solved
Functional benefit
Brands
- qXR: Chest X-ray AI reporting and triage solution; includes sub-products such as qXR-Detect, qXR-LN (lung nodule detection), qXR-PTX-PE (pneumothorax and pleural effusion), and qXR-CTR (heart failure risk indicator).
- qTrack
- qER
- qMSK
- qCT LN Quant
- Aira
- qScout
- Qure AI App
Products and services
- qXR (Chest X-ray Reporting)
- qER (Stroke & Traumatic Brain Injury)
- Lung Nodule Management (qCT LN Quant)
- qTrack (TB Care Cascades)
- qMSK (Musculoskeletal X-Ray Reporting)
- Heart Failure (qXR-CTR)
- Aira (Multi-Disease Clinical AI Co-Pilot)
- Qure AI App
Quantifiable outcome
- 26.7% of initially missed lung nodules detected on routine chest X-rays using qXR-LN, including 40% of early-stage cancers and 50% of missed Stage 1A nodules (University Hospitals Cleveland Medical Center study)
- +9 more outcomes
Companies that use Qure AI
Customer profileNamed customers37 records
Segments6 records
Ideal customer profiles5 records
Qure AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability10 records
Feature8 records
Qure AI partnerships and signals
Strategic signalPartnerships
33 partnerships are on record, tiered flagship, core and minor.
- AstraZenecaflagshipMulti-program strategic partnership under the EDISON Alliance's 1 Billion Lives Challenge to screen 5 million patients by 2025 for lung cancer risk in Colombia, El Salvador, India, and other LMICs. Joint lung cancer screening programs in Telangana (20 hospitals), Goa, Philippines, and Latin America. Co-development of A.Catalyst Network initiatives and combined pharma-AI care pathways.
- MicrosoftflagshipPartnership to expand access to Qure.ai's lung cancer detection and management suite in the United States (announced November 2025). Joint go-to-market leveraging Microsoft's cloud and healthcare channels for US-based deployments.
- Medtronic IndiacoreHub-and-spoke stroke care partnership in India integrating Qure.ai's AI CT analysis with Medtronic's stroke network to expedite treatment for nearly two million stroke patients annually.
- Project Data SpherecoreCo-developing autoRECIST AI for imaging-based tumor burden measurements in oncology clinical trials and routine cancer care, announced January 2024.
- Roche (Startup Creasphere APAC)coreJoined Roche's Startup Creasphere APAC program to co-create strategies supporting clinicians and improving patient outcomes in APAC through early detection enabled by AI (October 2024).
- Johnson & Johnson MedtechcorePartnership to boost early detection of lung cancer in India, integrating Qure.ai AI solutions with J&J Medtech lung cancer initiatives (announced May 2025).
- FujifilmflagshipValidated on Fujifilm's AI-enabled platform REiLI and partnered with Fujifilm and IHVN to accelerate TB screening in rural Nigerian communities (2021, 2023). Co-delivered solutions across global health programs.
- Siemens HealthineersflagshipValidated partner on Siemens Healthineers AI portfolio; collaboration with the Global Fund to accelerate AI adoption for TB diagnosis (2023); recipient of Siemens Healthineers Startup Award 2024.
- PhilipscorePartner logo displayed on the Qure.ai homepage indicating technology integration and co-distribution across Philips imaging and AI portfolio.
- Blackford AnalysiscoreListed as a distribution/integration partner on the Qure.ai homepage, deploying Qure.ai neurocritical AI solutions into A&E settings including Milton Keynes University Hospital.
- VillageReachcorePartnership to strengthen Mozambique's AI-enabled pandemic preparedness system, announced May 2026.
- Horizon Health Network (Canada)coreProvince-wide partnership to advance early lung cancer detection across New Brunswick, Canada, announced December 2025.
- Yashoda Hospital Hitech CitycoreLaunched an AI-enabled Lung Nodule Clinic with Qure.ai to strengthen early lung cancer detection and lung health, announced November 2025.
- PenRAD Imaging NetworkminorDeployed AI-Powered Chest CT for early lung cancer detection via Qure.ai, announced April 2025.
- Government of Goa (India)flagshipPublic-private partnership with AstraZeneca and Qure.ai to perform AI-enabled chest X-ray screening; over 1 lakh X-rays reviewed identifying 18 lung cancer cases. Extended MoU announced April 2025.
- Government of Telangana (India)flagshipMoU with AstraZeneca Pharma India and Qure.ai to deploy AI-powered lung cancer screening across 20 public hospitals, announced April 2026.
- Erasmus MC (Rotterdam)coreLaunched AI Innovation Centre for Medical Imaging in September 2022 and extended collaboration in December 2024 for early lung cancer detection.
- deepccorePartnership to empower care teams with AI-enhanced patient care workflows by integrating Qure.ai AI into deepc's platform (November 2023).
- Nuance (Microsoft)coreJoined Nuance Precision Imaging Network to enhance patient outcomes with AI-integrated workflows for care teams (April 2023).
- Medica GroupcoreStrategic partnership integrating Qure.ai augmented intelligence into Medica Group's teleradiology services for the UK, supporting faster stroke and neurocritical reporting.
- InHealth (UK)minorPartnership to enhance quality of telereporting services with Qure.ai's AI-powered chest X-ray solution (May 2023).
- USARADminorPartnership expanded Qure.ai presence into US teleradiology market (October 2023).
- Strategic Radiology (US)minorCollaboration to assist radiology workflows with Qure.ai AI-powered imaging (June 2024).
- UnilabsminorUnilabs signed on Qure.ai for triaging chest X-rays (July 2022).
- TherapixelminorPartnership to improve access to breast cancer detection through AI (March 2023).
- xWave TechnologiesminorStrategic collaboration announced August 2023.
- Healthcare Imaging Services (Australia)minorPartnership to bring AI chest X-ray diagnosis to Australia (July 2021).
- Nordic MedTechminorPartnership to provide radiology practices with Qure.ai AI technology (July 2020).
- PATH IndiacoreImplementation partner for AI-enabled chest X-ray solution for TB and COVID-19 screening in Maharashtra through Unitaid funding (2021-2023). Joint lung cancer early detection initiative with AstraZeneca in LMICs (2022).
- USAIDcoreUSAID-supported SAMRIDH Healthcare Blended Finance Facility supports Qure.ai to strengthen India's healthcare systems (April 2022); joint program to enhance diagnostics (September 2023).
- IHVN (Institute of Human Virology Nigeria)minorPartnered with Fujifilm and Qure.ai to accelerate TB screening in rural Nigerian communities (August 2022).
- CIDRZ (Centre for Infectious Disease Research in Zambia)minorPartnered with Qure.ai for TB screening (July 2022).
- Fractal AnalyticsflagshipQure.ai is referenced as a Fractal Analytics subsidiary in Fractal's Q4 FY26 commentary (May 2026). Fractal showcased a partnership with Qure.ai for rapid TB detection in radiology at the India AI Impact Summit 2026.
Scale indicators20 records
Recent moves8 records
Expansion highlights8 records
Qure AI competitors and assessment
Company assessmentDirect peers
- Lunit: South Korea-based AI medical imaging company with flagship INSIGHT CXR for chest X-ray triage and Lunit SCOPE for biomarker analysis — directly competing with Qure.ai's qXR in chest X-ray AI for lung cancer and TB detection across hospital systems.
- Nanox AI (formerly Zebra Medical Vision): AI imaging algorithms for chest, bone, and other modalities distributed through the Nanox platform; overlaps with Qure.ai's qXR chest X-ray and broader imaging AI footprint.
- Aidoc: AI medical imaging company offering a suite of FDA-cleared algorithms for CT/MRI triage across multiple findings; directly comparable to Qure.ai's qER and broader imaging AI strategy aimed at hospital radiology workflows.
- Annalise.ai: Comprehensive AI radiology platform covering chest X-ray, CT, and head CT findings — closely comparable to Qure.ai's multi-modality imaging portfolio and enterprise hospital go-to-market.
- Viz.ai: Specialist in AI-powered stroke detection and care coordination on head CT, the most direct competitor to Qure.ai's qER for stroke triage and hub-and-spoke workflow.
Others
- Blackford Analysis: Medical imaging AI aggregator and distribution platform that resells/embeds Qure.ai algorithms alongside competitor algorithms; relevant as a channel peer and AI marketplace operator shaping hospital AI procurement.
Emerging players
- Therapixel: AI mammography (MammoScreen) and breast cancer detection — overlaps with Qure.ai's life sciences and screening thesis; also a named Qure.ai partner, indicating close ecosystem positioning.
- HeartFlow: AI-driven cardiac diagnostics (FFR-CT) for coronary artery disease; comparable as a specialty AI imaging company with regulatory clearances, hospital system sales motion, and clinical-evidence-led go-to-market akin to Qure.ai's heart-failure and lung nodule modules.
Broad incumbents
- Philips: Global imaging and health technology incumbent with its own AI imaging suite; operates as a Qure.ai technology and distribution partner, and competes broadly in radiology AI decision support.
- Siemens Healthineers: Global imaging modality OEM with its own AI-Rad Companion portfolio and validated-Qure.ai partner on REiLI equivalent; relevant as both a broad incumbent competitor and an OEM distribution channel for Qure.ai.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Qure AI social profiles
Digital presenceQure AI compliance and trust
Trust signalCompliance6 records
Qure AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qure AI leadership team
Management profileNumber of profiles
Profiles15 records
Qure AI subsidiaries and ownership
Company hierarchySubsidiaries1 record
Qure AI funding detail
Funding detailFunding overview
Funding rounds5 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qure AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qure AI
What does Qure AI do?
Qure AI develops deep-learning medical imaging software that interprets chest X-rays, head CTs, chest CTs, and musculoskeletal X-rays for clinical decision support. Its portfolio (qXR, qER, qCT LN Quant, qTrack, qMSK, Aira, qXR-CTR) is sold to hospitals, NHS trusts, teleradiology firms, government public-health programs, OEM imaging vendors, and pharmaceutical/life-sciences organizations.
Is Qure AI a public or private company?
Qure AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was Qure AI founded?
Qure AI was founded in 2016. It employs 251 to 500 people.
Where is Qure AI based?
Qure AI is headquartered in Andheri, India, in the Asia region.
How does Qure AI make money?
Five revenue lines are on record. Enterprise SaaS subscriptions are the primary driver. The others are OEM/embedded licensing, government and public health program contracts, pharma & life sciences clinical trial services and grants and non-dilutive funding.
Who are Qure AI's main competitors?
Direct peers on record are Lunit, Nanox AI (formerly Zebra Medical Vision), Aidoc, Annalise.ai and Viz.ai. Blackford Analysis is listed as an others. Emerging players are Therapixel and HeartFlow. Broad incumbents are Philips and Siemens Healthineers.
Does Qure AI have an API?
No public API is recorded for Qure AI.
What industry is Qure AI in?
Qure AI's product category is Medical Imaging AI. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 51321 and its SIC code is 3841.